147 related articles for article (PubMed ID: 35707375)
1. Time Intervals between Double Primary Breast and Ovarian Cancers and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis.
He XQ; Gao YT; Zhang X; Jiang H
Biomed Res Int; 2022; 2022():4557346. PubMed ID: 35707375
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of women with metachronous breast and ovarian carcinomas.
Liou WS; Hamilton CA; Cheung MK; Osann K; Longacre TA; Teng NN; Husain A; Dirbas FM; Chan JK
Gynecol Oncol; 2006 Oct; 103(1):190-4. PubMed ID: 16569424
[TBL] [Abstract][Full Text] [Related]
3. Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center.
Tasca G; Dieci MV; Baretta Z; Faggioni G; Montagna M; Nicoletto MO; Peccatori FA; Guarneri V; Colombo N
Front Oncol; 2020; 10():608783. PubMed ID: 33381461
[TBL] [Abstract][Full Text] [Related]
4. Synchronous and Metachronous Breast and Ovarian Cancers: Experience from a Single Tertiary Care Cancer Centre in India.
Joshi S; Murali-Nanavati S; Shylasree TS; Hawaldar R; Tripathi S; Sahay A; Noronha J; Jain U; Thomas A; Kowtal P; Vanmali V; Nair NS; Parmar V; Badwe RA; Sarin R
Indian J Surg Oncol; 2023 Dec; 14(4):809-821. PubMed ID: 38187845
[TBL] [Abstract][Full Text] [Related]
5. Survival of Patients with First and Metachronous Second Primary Breast Cancer or Lung Cancer Malignancy: Comparisons Using the SEER Database.
Zhong M; He X; Lei K
Adv Ther; 2020 May; 37(5):2236-2245. PubMed ID: 32274747
[TBL] [Abstract][Full Text] [Related]
6. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
7. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.
Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M
Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Patients with Primary Breast Cancer Following Primary Ovarian Cancer.
Zhang W; Zhang W; Lin Z; Wang F; Li M; Zhu L; Yu Y; Gao Y
Med Sci Monit; 2019 May; 25():3869-3879. PubMed ID: 31125329
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
Wong SM; Ajjamada L; Weiss AC; Prakash I; Skamene S; Boileau JF; Pollak MN; Basik M
Cancer; 2022 Apr; 128(7):1365-1372. PubMed ID: 34919263
[TBL] [Abstract][Full Text] [Related]
10. Meningioma and breast cancer: survival of patients with synchronous and metachronous meningioma and breast cancer.
Lavrador JP; Pinto MV; Lemos LM; Ribeiro C; Santos AP
J Neurooncol; 2018 Jan; 136(1):163-171. PubMed ID: 29119423
[TBL] [Abstract][Full Text] [Related]
11. Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study.
Wang S; Hu S; Huang S; Su L; Guo Q; Wu B; Ye J; Zhang D; Zhang Y; Zhang W; Wei Y
Medicine (Baltimore); 2023 Feb; 102(6):e32772. PubMed ID: 36820587
[TBL] [Abstract][Full Text] [Related]
12. Metastasis, characteristic, and treatment of breast cancer in young women and older women: A study from the Surveillance, Epidemiology, and End Results registration database.
Gao X; Zhang F; Zhou Q; Xu H; Bian J
PLoS One; 2023; 18(11):e0293830. PubMed ID: 37917616
[TBL] [Abstract][Full Text] [Related]
13. Second primary malignancies after ovarian cancer: A SEER-based analysis (1975-2016).
Yang Z; Liu X; Yang X; Liao QP
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):80-85. PubMed ID: 35181052
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer.
Zhang L; Wu Y; Liu F; Fu L; Tong Z
Oncotarget; 2016 Aug; 7(32):52450-52459. PubMed ID: 27223440
[TBL] [Abstract][Full Text] [Related]
15. Risk of Second Primary Tumors After Childhood and Adolescent Ovarian Malignancies: A SEER Analysis (1973-2011).
Nasioudis D; Ramer I; Sisti G; Fambrini M
J Pediatr Adolesc Gynecol; 2015 Dec; 28(6):522-5. PubMed ID: 26152647
[TBL] [Abstract][Full Text] [Related]
16. Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis.
Peng P; Chen JY; Han YT; Chen X; Li HY; Hu CH; Wang JL
BMC Surg; 2021 Oct; 21(1):378. PubMed ID: 34702227
[TBL] [Abstract][Full Text] [Related]
17. Do prognoses of patients with second primary cancers differ from those of patients with no prior cancer? A population-based study.
Kudo H; Morishima T; Fujii M; Nagayasu M; Sobue T; Ohno Y; Miyashiro I
Cancer Epidemiol; 2022 Oct; 80():102218. PubMed ID: 35870232
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database.
Han Y; Wang X; Li X; Chen J; Ouyang L; Li Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16407-16415. PubMed ID: 37707575
[TBL] [Abstract][Full Text] [Related]
19. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.
Fosså SD; Chen J; Schonfeld SJ; McGlynn KA; McMaster ML; Gail MH; Travis LB
J Natl Cancer Inst; 2005 Jul; 97(14):1056-66. PubMed ID: 16030303
[TBL] [Abstract][Full Text] [Related]
20. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer.
Galper S; Gelman R; Recht A; Silver B; Kohli A; Wong JS; Van Buren T; Baldini EH; Harris JR
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):406-14. PubMed ID: 11872286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
